Jardiance Met 12.5mg/500mg (Empagliflozin/Metformin)

Jardiance Met 12.5mg/500mg combines Empagliflozin and Metformin, offering enhanced blood sugar control for adults with type 2 diabetes. Empagliflozin is an SGLT2 inhibitor that works by helping the kidneys remove excess glucose through urine, while Metformin reduces glucose production in the liver and improves the body’s response to insulin. This dual-action formula is effective for patients who require stronger control than monotherapy provides.

Along with regulating blood glucose, Jardiance Met may contribute to weight loss and supports cardiovascular protection, especially in diabetic patients with heart-related risks. The 12.5mg dose of Empagliflozin provides a more intensive SGLT2 response, making it suitable for those who haven’t achieved desired results with lower strengths. The tablet should be taken with meals to reduce stomach discomfort and should be used alongside proper diet, exercise, and routine blood sugar monitoring.